Theranos has received much praise along with a healthy dose of skepticism in recent months as they have “gone public” with their potentially disruptive laboratory solution.
Behind all of the press, there is one qualifying question: Has Theranos scaled microfluidic technology across a comprehensive menu of tests?
If the answer to this question is “Yes” the lab industry will never be the same. Simply put, if microfluidic technology is able to address a broad swath of the CMS laboratory menu, then the current centralized high throughput laboratory model will soon be obsolete. If the answer is “No”, then all of this attention is for naught and Theranos will join a long list of exciting technology businesses that failed to commercialize.
This report explores the disruptive attributes that Theranos is claiming and discuss the likelihood that they have cracked the code of scaling microfluidics. Also it explores the various distribution outlets Theranos is pursuing, with a particular emphasis on the Walgreens partnership – a partnership which will, if successful, drive disruptive change far beyond laboratory diagnostics, potentially redefining primary care, patient access, chronic disease management, and population health.
For more information visit http://www.researchandmarkets.com/research/79lcd4/will_theranos.
